Allakos Inc. (ALLK): Price and Financial Metrics

Allakos Inc. (ALLK): $1.11

0.10 (-8.26%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add ALLK to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#248 of 360

in industry

ALLK Price/Volume Stats

Current price $1.11 52-week high $5.64
Prev. close $1.21 52-week low $1.00
Day low $1.10 Volume 409,700
Day high $1.21 Avg. volume 1,366,535
50-day MA $1.31 Dividend yield N/A
200-day MA $2.48 Market Cap 97.54M

ALLK Stock Price Chart Interactive Chart >


Allakos Inc. (ALLK) Company Bio


Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. The company was founded in 2012 and is based in San Carlos, California.


ALLK Latest News Stream


Event/Time News Detail
Loading, please wait...

ALLK Latest Social Stream


Loading social stream, please wait...

View Full ALLK Social Stream

Latest ALLK News From Around the Web

Below are the latest news stories about ALLAKOS INC that investors may wish to consider to help them evaluate ALLK as an investment opportunity.

Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q3 2023

Financial Highlights and Business Updates from Allakos's Latest Earnings Filing

Yahoo | November 13, 2023

Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results

SAN CARLOS, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2023. Recent Allakos Events Completed enrollment in both the Phase 2 study of subcutaneous lirentelimab in patients with atopic dermatitis and the Phase 2b study of subcutaneous

Yahoo | November 13, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping tabs on for Thursday morning!

William White on InvestorPlace | November 9, 2023

Following a 63% decline over last year, recent gains may please Allakos Inc. (NASDAQ:ALLK) institutional owners

Key Insights Given the large stake in the stock by institutions, Allakos' stock price might be vulnerable to their...

Yahoo | November 6, 2023

Why Shares of Allakos Are Up Wednesday

Shares of clinical-stage biotech company Allakos (NASDAQ: ALLK) were up more than 15% as of 11:40 a.m. on Wednesday. Despite the rise, Allakos' stock is still down more than 70% so far this year. Allakos focuses on monoclonal antibodies to trigger responses in the body's immune cells to treat various conditions, including allergies, and inflammatory and proliferative diseases.

Yahoo | September 27, 2023

Read More 'ALLK' Stories Here

ALLK Price Returns

1-mo -14.94%
3-mo -62.88%
6-mo -43.37%
1-year -70.56%
3-year -89.68%
5-year -70.48%
YTD -59.34%
2023 -67.58%
2022 -13.99%
2021 -30.07%
2020 46.81%
2019 82.44%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!